Estudio del polimorfismo de debrisoquina en una muestra de la población cubana

the differences in the capacity with which every individual metabolises a drug by a specific route has a clinical relevance for widely used drugs of a narrow safety range if that is the main route in the elimination of the drug, or if the number of therapeutic alternatives is limited; therefore, the pharmacogenetic information is essential in the personalized therapeutics and it contributes to a rational use of drugs. as the cytochrome p4502d6 (cyp2d6) catalyzes more than 65% of the commonly used drugs, the aim of this paper was to identify different cyp2d6 metabolising phenotypes in a sample of 104 subjects of the cuban population by determining the metabolic ratio between urinary concentrations of debrisoquine and its metabolite 4oh-debrisoquine, quantified by high performance liquid chromatography. we found that 3.84% of the individuals studied were slow metabolisers.